Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 How COVID unlocked the power of RNA vaccines.

Literature DB >> 33437061

How COVID unlocked the power of RNA vaccines.

Elie Dolgin.

Abstract

Entities: Disease

Keywords: Drug discovery; Immunology; SARS-CoV-2; Vaccines

Mesh：

Substances：

Year: 2021 PMID： 33437061 DOI： 10.1038/d41586-021-00019-w

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

8 in total

1. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

Authors: Alec W Freyn; Jamile Ramos da Silva; Victoria C Rosado; Carly M Bliss; Matthew Pine; Barbara L Mui; Ying K Tam; Thomas D Madden; Luís Carlos de Souza Ferreira; Drew Weissman; Florian Krammer; Lynda Coughlan; Peter Palese; Norbert Pardi; Raffael Nachbagauer
Journal: Mol Ther Date: 2020-04-19 Impact factor: 11.454

2. Vaccines 'on demand': science fiction or a future reality.

Authors: Jeffrey B Ulmer; Monique K Mansoura; Andrew J Geall
Journal: Expert Opin Drug Discov Date: 2015-01-13 Impact factor: 6.098

3. Nonviral delivery of self-amplifying RNA vaccines.

Authors: Andrew J Geall; Ayush Verma; Gillis R Otten; Christine A Shaw; Armin Hekele; Kaustuv Banerjee; Yen Cu; Clayton W Beard; Luis A Brito; Thomas Krucker; Derek T O'Hagan; Manmohan Singh; Peter W Mason; Nicholas M Valiante; Philip R Dormitzer; Susan W Barnett; Rino Rappuoli; Jeffrey B Ulmer; Christian W Mandl
Journal: Proc Natl Acad Sci U S A Date: 2012-08-20 Impact factor: 11.205

4. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.

Authors: Martin Alberer; Ulrike Gnad-Vogt; Henoch Sangjoon Hong; Keyvan Tadjalli Mehr; Linus Backert; Greg Finak; Raphael Gottardo; Mihai Alexandru Bica; Aurelio Garofano; Sven Dominik Koch; Mariola Fotin-Mleczek; Ingmar Hoerr; Ralf Clemens; Frank von Sonnenburg
Journal: Lancet Date: 2017-07-25 Impact factor: 79.321

5. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.

Authors: Robert A Feldman; Rainard Fuhr; Igor Smolenov; Amilcar Mick Ribeiro; Lori Panther; Mike Watson; Joseph J Senn; Mike Smith; Ӧrn Almarsson; Hari S Pujar; Michael E Laska; James Thompson; Tal Zaks; Giuseppe Ciaramella
Journal: Vaccine Date: 2019-05-10 Impact factor: 3.641

6. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

Authors: F Martinon; S Krishnan; G Lenzen; R Magné; E Gomard; J G Guillet; J P Lévy; P Meulien
Journal: Eur J Immunol Date: 1993-07 Impact factor: 5.532

7. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Authors: Armin Hekele; Sylvie Bertholet; Jacob Archer; Daniel G Gibson; Giuseppe Palladino; Luis A Brito; Gillis R Otten; Michela Brazzoli; Scilla Buccato; Alessandra Bonci; Daniele Casini; Domenico Maione; Zhi-Qing Qi; John E Gill; Nicky C Caiazza; Jun Urano; Bolyn Hubby; George F Gao; Yuelong Shu; Ennio De Gregorio; Christian W Mandl; Peter W Mason; Ethan C Settembre; Jeffrey B Ulmer; J Craig Venter; Philip R Dormitzer; Rino Rappuoli; Andrew J Geall
Journal: Emerg Microbes Infect Date: 2013-08-14 Impact factor: 7.163

8. A Thermostable mRNA Vaccine against COVID-19.

Authors: Na-Na Zhang; Xiao-Feng Li; Yong-Qiang Deng; Hui Zhao; Yi-Jiao Huang; Guan Yang; Wei-Jin Huang; Peng Gao; Chao Zhou; Rong-Rong Zhang; Yan Guo; Shi-Hui Sun; Hang Fan; Shu-Long Zu; Qi Chen; Qi He; Tian-Shu Cao; Xing-Yao Huang; Hong-Ying Qiu; Jian-Hui Nie; Yuhang Jiang; Hua-Yuan Yan; Qing Ye; Xia Zhong; Xia-Lin Xue; Zhen-Yu Zha; Dongsheng Zhou; Xiao Yang; You-Chun Wang; Bo Ying; Cheng-Feng Qin
Journal: Cell Date: 2020-07-23 Impact factor: 41.582

8 in total

20 in total

How COVID unlocked the power of RNA vaccines.

1. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice.

2. Vaccines 'on demand': science fiction or a future reality.

3. Nonviral delivery of self-amplifying RNA vaccines.

4. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.

5. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.

6. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

7. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

8. A Thermostable mRNA Vaccine against COVID-19.

Review 1. Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.

Review 2. [Malarial antigens in the era of mRNA vaccines].

3. RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy.

Review 4. An Update on Self-Amplifying mRNA Vaccine Development.

Review 5. The Limitless Future of RNA Therapeutics.

6. The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland.

7. Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine.

Review 8. Delivery Strategies for mRNA Vaccines.

Review 9. Mucosal vaccines - fortifying the frontiers.

Review 10. Developmental Aspects of SARS-CoV-2, Potential Role of Exosomes and Their Impact on the Human Transcriptome.